49th week of 2015 patent applcation highlights part 25 |
Patent application number | Title | Published |
20150344513 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF FONDAPARINUX - The present invention relates to methods for the synthesis of fondaparinux and intermediates thereto. | 2015-12-03 |
20150344514 | CHEMICALLY CLEAVABLE GROUP - Disclosed is the use of the reactive components of the inverse electron-demand Diels Alder reaction for chemical masking and unmasking in vitro. This can be applied in complex chemical reactions and, particularly in the synthesis of biomolecules, e.g. on solid supports. The reactive components are a dienophile, particularly a trans-cyclooctene, and a diene, particularly a tetrazine. | 2015-12-03 |
20150344515 | SELECTED MACROLIDES WITH PDE4-INHIBITING ACTIVITY - The application relates to the macrolide compound of the formula (I): wherein * indicates a stereocentre which is in (R) or (S) configuration, or a pharmaceutically acceptable salt or ester thereof and their use as PDE4 inhibitors. | 2015-12-03 |
20150344516 | LABELLED NUCLEOTIDES - The invention provides a nucleotide or nucleoside having a base attached to a detectable label via a cleavable linker, characterised in that the cleavable linker contains a moiety selected from the group comprising: Formula (I) (wherein X is selected from the group comprising O, S, NH and NQ wherein Q is a C | 2015-12-03 |
20150344517 | STABLE INDOLE-3-PROPIONATE SALTS OF S-ADENOSYL-L-METHIONINE - Stable indole-3-propionic acid salts of S-adenosyl-L-methionine, or a pharmaceutically acceptable salt thereof, are disclosed, as well as pharmaceutical compositions comprising the indole-3-propionic acid salts, methods of using the indole-3-propionic acid salts and processes for making same. | 2015-12-03 |
20150344518 | ESTROGEN RECEPTOR IMAGING AGENTS - Compounds useful for molecular imaging of cells expressing estrogen receptors are provided. Also provided are intermediates for making the compounds and methods of making the compounds using a modular convergent strategy. Further, methods of making the intermediates are described, as well as methods of diagnosing disease in a subject by using the compounds as imaging agents. | 2015-12-03 |
20150344519 | METHOD OF SYNTHESIZING PEPTIDES, PROTEINS AND BIOCONJUGATES - The invention relates to the synthesis of peptides, proteins and related bioconjugates, and in particular, to such synthesis using a peptide ligation method whereby a C-terminal salicylaldehyde ester peptide is reacted with an aminoacyl-N-hydroxl peptide. The invention also relates to the synthesis of cyclic peptides, including serinyl- or threonyl-containing cyclic peptides. The invention further relates to a solid phase synthesis of C-terminal salicylaldehyde ester peptides. | 2015-12-03 |
20150344520 | CHROMATOGRAPHY MEDIA AND PROTEIN PURIFICATION METHOD USING THE SAME - A chromatography media having excellent salt tolerance, adsorption characteristics and so forth is provided. The chromatography media contains a base media involving porous particles and polyamine bonded with the base media, in which 20 to 40% of amino groups in the polyamine is modified with a hydrophobic group. | 2015-12-03 |
20150344521 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES - Provided are compounds of Formula I: | 2015-12-03 |
20150344522 | AURISTATIN TYRAMINE PHOSPHATE SALTS AND AURISTATIN AMINOQUINOLINE DERIVATIVES AND PRODRUGS THEREOF - The present invention relates to new auristatin compounds and prodrugs thereof, compositions comprising them and uses thereof. | 2015-12-03 |
20150344523 | MUTANT AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING - The present application provides stable peptide-based Akt capture agents and methods of use as detection and diagnosis agents and in the treatment of diseases and disorders. The application further provides methods of manufacturing Akt capture agents using iterative on-bead in situ click chemistry. | 2015-12-03 |
20150344524 | MODIFIED APIDAECIN DERIVATIVES AS ANTIBIOTIC PEPTIDES - This invention relates to modified antibiotic peptides, particularly for use in medicine. The invention further relates to compositions and methods for destroying microorganisms, such as bacteria, viruses or fungi, and to methods for treating microbial infections. The object of the invention is to develop novel antibiotic peptides, particularly having enhanced antibiotic activity and an expanded spectrum of activity against other strains of bacteria, particularly gram-positive bacteria such as | 2015-12-03 |
20150344525 | A DUAL-TARGETED THERAPEUTIC PEPTIDE FOR NASOPHARYNGEAL CARCINOMA, NANOPARTICLES CARRYING SAME AND USES THEREOF - Disclosed is a dual-targeted therapeutic peptide for nasopharyngeal carcinoma formed by covalently linking a targeted therapeutic peptide for nasopharyngeal carcinoma, a peptide linker and a targeted therapeutic peptide with an α-helical structure for nasopharyngeal carcinoma. Also disclosed is a nanoparticle containing the peptide. The peptide and the nanoparticle can be used to treat nasopharyngeal carcinoma. | 2015-12-03 |
20150344526 | BIOLOGICALLY ACTIVE COMPLEX AND ITS PREPARATION - A biologically active complex comprising either a polypeptide having the sequence of a variant of a naturally occurring protein, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein; or a peptide of up to 50 amino acids, for instance a fragment of the naturally occurring protein or a variant thereof; and a pharmaceutically acceptable salt of a fatty acid or lipid. The complexes of the invention demonstrate a novel mode of action, which gives rise to opportunities for the development of further active agents and screening methods. | 2015-12-03 |
20150344527 | ANTIMICROBIAL PEPTIDES, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF - Antimicrobial peptides such as, for example, the peptides shown in SEQ ID No 1, SEQ ID No 2, SEQ ID No 3, SEQ ID No 4 or SEQ ID No 5. The peptides have activity against Gram positive bacteria and against Gram negative bacteria. A bactericidal composition is also provided, which may comprise an amount between 0.5 μg/mL and 1024 μg/mL of the peptides; and excipients. | 2015-12-03 |
20150344528 | RECOMBINANT NON-PATHOGENIC MAREK'S DISEASE VIRUS CONSTRUCTS ENCODING INFECTIOUS LARYNGOTRACHEITIS VIRUS AND NEWCASTLE DISEASE VIRUS ANTIGENS - The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus and Newcastle Disease virus protein antigens, and methods of their use in poultry vaccines. | 2015-12-03 |
20150344529 | VACCINE FOR HPV INFECTION AND/OR HEPATITIS B COMPRISING HPV/HBS CHIMERIC PROTEIN AS ACTIVE INGREDIENT - A chimeric protein of HPV-L2 peptide and HBs protein wherein the HPV-L2 peptide is (1) a peptide consisting of the core sequence region of 20 amino acid residues, (2) a peptide inside the core sequence region comprising 6 amino acid residues Gly-Gly-Leu-Gly-Ile-Gly or (3) a peptide consisting of 70 or less amino acid residues obtained by adding an amino acid sequence derived from HPV L2 protein at the N-terminal and/or the C-terminal of the core sequence region; and a vaccine for HPV infection and/or hepatitis B comprising the chimeric protein as an active ingredient. A vaccine comprising the chimeric protein of the present invention is the one that has an increased expression level in a host, an enhanced immune ability (early antibody induction) and a broader spectrum effective for a number of HPV types. | 2015-12-03 |
20150344530 | Synthetic Peptides as Carriers for Conjugation with Polysaccharides - The invention is directed to compositions and methods for the manufacture and administration of vaccines wherein the peptide comprises at least 28 amino acid residues of pneumococcal surface adhesion A and, in particular compositions, methods and tools for the conjugation of peptides with polysaccharides and other chemical agents in the formulation of vaccines. | 2015-12-03 |
20150344531 | MEDICAMENT FOR LCT POISONING - The medicament for the prevention or the relief of poisoning by large clostridial cytotoxins (LCTs), in particular | 2015-12-03 |
20150344532 | ENGINEERED XYLOSE TRANSPORTERS WITH REDUCED GLUCOSE INHIBITION - Provided herein are compositions and methods useful for reducing glucose inhibition in transporting xylose, arabinose and other monosaccharides, into a yeast cell. | 2015-12-03 |
20150344533 | NUCLEIC ACID MODULATORS OF GLYCOPROTEIN VI - The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures. | 2015-12-03 |
20150344534 | OSTEOPONTIN VARIANTS FOR USE IN SUPPRESSION OR PREVENTION OF TUMOR GROWTH AND COMPOSITIONS CONTAINING SUCH OSTEOPONTIN VARIANTS - The present invention relates to pharmaceutical compositions and nutritional supplements comprising an osteopontin variant, and medical use of such compositions and supplements for treating or preventing tumor-generating cancer. | 2015-12-03 |
20150344535 | NEUROTROPHIN-TYROSINE KINASE RECEPTOR SIGNALING - The invention relates to a method of regulating neurotrophin-tyrosine kinase receptor signaling in a cell comprising modulating the interaction between the juxtamembrane region of the intracellular domain of the neurotrophin receptor p75 and Trk. The invention also relates to compositions comprising compounds which modulate the interaction between the juxtamembrane region of the intracellular domain of the neurotrophin receptor p75 and Trk, and use of the compounds and compositions for the treatment of neurotrophin-Trk signaling related diseases and disorders. | 2015-12-03 |
20150344536 | VARIANT OF BPIFB4 PROTEIN - The present invention relates to a variant of BPIFB4 (Bactericidal/Permeability Increasing protein family B, member 4) protein and to its use for the treatment of pathologies involving impairment of nitric oxide signalling. | 2015-12-03 |
20150344537 | Non-Transgene Transfection for Therapeutic Purposes - This disclosure describes compositions and methods involved in tumor suppression and inhibiting infection of cells by pathogens. Generally, the compositions include an mRNA cargo that can provide a therapeutic benefit after being introduced into an epithelial cell. In some cases, the mRNA can encode a polypeptide. In some cases, the polypeptide can suppress epithelial cell proliferation. In other embodiments, the polypeptide can be involved in innate immunity. In various embodiments, the polypeptide can include cathelicin antimicrobial protein (CAMP), calprotectin, S100A8, S100A9, a β-defensin, S100A7, secretory leukocyte inhibitor, lipocalin 2, or lysozyme. In some embodiments, the mRNA can include a stabilizing moiety such as, for example, a 5′ cap or a 3′ extension. | 2015-12-03 |
20150344538 | NOVEL SPECIFIC-BINDING PROTEINS AND USES THEREOF - The present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q16552 and novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q9NPF7. In addition, the present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against one or both of Swiss Prot Q16552 and Swiss Prot Q9NPF7. The invention also relates to nucleic acid molecules encoding such polypeptides and to methods for generation of such polypeptides and nucleic acid molecules. In addition, the invention is directed to compositions comprising the polypeptides, and therapeutic and/or diagnostic uses of these polypeptides. | 2015-12-03 |
20150344539 | BINDING PROTEINS INHIBITING THE VEGF-A RECEPTOR INTERACTION - The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration. | 2015-12-03 |
20150344540 | NOVEL GLP-1 RECEPTOR AGONISTS WITH CHOLESTEROL EFFLUX ACTIVITY - The present invention provides novel glucagon-like protein-1 (GLP-1) receptor agonist compounds that promote cholesterol efflux. The ABCA1-mediated cholesterol efflux present invention also provides compositions comprising the novel glucagon-like protein-1(GLP-1) receptor agonist compounds, and relates to the use of said compounds in therapy, to methods of treatment comprising administration of said compounds to patients, and to the use of said compounds in the manufacture of medicaments. | 2015-12-03 |
20150344541 | PLATELET TARGETED TREATMENT - The present disclosure relates to compositions and methods for targeting expression of exogenous genes to platelets. In particular, the present disclosure relates to treatment of hemophilia and other diseases and conditions by targeting expression of exogenous agents (e.g., clotting factors) to platelets. | 2015-12-03 |
20150344542 | PARTIAL PURIFICATION METHOD FOR HYDROPHILIC RECOMBINANT PROTEIN - The present invention relates to a method for partially purifying a hydrophilic recombinant protein from a host expressing a hydrophilic recombinant protein. The method includes: a solution acquisition step in which a dissolving solvent is added to the host expressing a hydrophilic recombinant protein so as to dissolve the host cell and an insoluble substance is separated therefrom so as to obtain a solution. The hydrophilic recombinant protein has a hydropathy index of 0 or less, and the dissolving solvent is an aprotic polar solvent. Preferably, the solution is subjected to solvent substitution using an aqueous solvent. | 2015-12-03 |
20150344543 | COMPOSITIONS EMPLOYING ALTERNATIVE READING FRAME POLYPEPTIDES FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASE - Provided are alternative reading frame (ARF) polypeptides as well as antigen presenting cell (APC) and dendritic cell (DC) based compositions that comprise ARF polypeptides. ARF polypeptides and ARF polypeptide-based compositions are useful in the treatment of cancer and infectious disease. | 2015-12-03 |
20150344544 | COMPOSITIONS AND METHODS RELATING TO UNIVERSAL GLYCOFORMS FOR ENHANCED ANTIBODY EFFICACY - The present disclosure relates to glycoproteins, particularly monoclonal antibodies, comprising a glycoengineered Fc region, wherein said Fc region comprises an optimized N-glycan having the structure of Sia | 2015-12-03 |
20150344545 | Method of Treating and Preventing Infectious Diseases Using Colostrum - A method of treating and/or preventing infectious disease in mammals, such as canines, includes administering an effective amount of a colostral composition to a mammal which has been produced by a donor mammal and includes at least one type of antibody having a binding specificity for at least one pathogen. The at least one type of antibody is generated by the donor mammal in response to being challenged with at least one challenge material. | 2015-12-03 |
20150344546 | Monoclonal Antibodies for Ebola and Marburg Viruses - Described herein are a number of Ebola monoclonal antibodies. | 2015-12-03 |
20150344547 | MONOCLONAL ANTIBODY AGAINST MURAMYL PEPTIDES - Disclosed is an isolated antibody or an antigen-binding fragment thereof. The antibody is capable of binding to a muramyl peptide, or a derivative or an analog or a salt thereof. The muramyl peptide comprises muramic acid and an amino acid selected from the group consisting of alanine, isoglutamine, glutamic acid, and a salt thereof. Also disclosed are methods of producing the antibody, compositions comprising the antibody, methods of treating using the antibody, uses of the antibody, methods of detecting muramyl peptide, an assay for detecting muramyl peptide, an antibacterial agent, hybridomas and kits. | 2015-12-03 |
20150344548 | Compositions and Methods for Treating and Preventing Staphylococcus Aureus Infections - Antibodies having Fab regions that specifically bind to | 2015-12-03 |
20150344549 | SPLIT INTEINS, CONJUGATES AND USES THEREOF - Disclosed herein are split inteins, fused proteins of split inteins, and methods of using split inteins to efficiently purify and modify proteins of interest. Thus, provided herein are fusion proteins of a polypeptide and a split intein N-fragment, or variant thereof, as described below in greater detail. Also provided are complexes of the fusion protein and a split intein C-fragment or variant thereof as described in detail below. The complex of the fusion protein and C-fragment or variant thereof can be via a covalent interaction between the fusion protein and C-fragment or variant or via a noncovalent interaction (e.g., ionic, H-bonding, and/or van der Waals interaction). Further provided herein are split intein C-fragments or variants thereof. | 2015-12-03 |
20150344550 | ANTI-NEUBLASTIN ANTIBODIES AND USES THEREOF - Antibodies and antigen binding fragments that bind to neublastin polypeptides are disclosed. Also disclosed are methods of using the antibodies and antigen binding fragments in assays for detecting the presence or amount of endogenous and/or exogenous neublastin in a sample and in methods of antagonizing neublastin bioactivity. | 2015-12-03 |
20150344551 | COMPOSITIONS AND METHODS FOR TREATMENT AND DETECTION OF CANCERS - Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, lung, breast, mouse, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervix, ovary, and/or prostate cancer. | 2015-12-03 |
20150344552 | ANTIBODY AGAINST THE PROTEIN TRIO AND ITS METHOD OF PRODUCTION - Disclosed are specific antibodies against the protein Trio, their method of production, and their use in in vitro cancer prognostic method. Also described are the antigens enabling production of the antibodies. | 2015-12-03 |
20150344553 | HUMAN ANTI-TAU ANTIBODIES - Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively. | 2015-12-03 |
20150344554 | BTNL9 Proteins, Nucleic Acids, and Antibodies and Uses Thereof - The invention provides novel BTNL9 proteins, including multimers, fragments, and variants of a human BTNL9 protein. In addition, antibodies that can bind to BTNL9 proteins and nucleic acids encoding BTNL9 proteins are provided. Uses for BTNL9 proteins, and agonists or antagonists thereof, are described. | 2015-12-03 |
20150344555 | ANTIBODY FORMULATIONS AND METHODS - Antibody formulations and methods useful for prophylaxis or treatment of amyloidosis, including AA amyloidosis and AL amyloidosis. | 2015-12-03 |
20150344556 | EXTRACELLULAR HISTONES AS BIOMARKERS FOR PROGNOSIS AND MOLECULAR TARGETS FOR THERAPY - Hyper-inflammatory responses can lead to a variety of diseases including sepsis. It is now shown that extracellular histones released in response to inflammatory challenge are mediators contributing to endothelial dysfunction, organ failure and death during sepsis. As such, they can be targeted pharmacologically by inhibitors, as well as used as biomarkers for prognosis of sepsis and other diseases. | 2015-12-03 |
20150344557 | Liquid Antibody Formulation With Improved Aggregation Properties - Disclosed here are methods and systems for improving the aggregation profile in a liquid antibody formulation. In one embodiment, the antibody is a fully monoclonal antibody that binds to Angiopoietin-2. | 2015-12-03 |
20150344558 | ANTI-IL-6 ANTIBODIES FOR THE TREATMENT OF ARTHRITIS - The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat rheumatoid arthritis. | 2015-12-03 |
20150344559 | ANTI-TNF-ALPHA GLYCOANTIBODIES AND USES THEREOF - The present disclosure relates to a novel class of anti-TNFα monoclonal antibodies or antigen binding fragments comprising a homogeneous population of anti-TNFα IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-TNFα monoclonal antibodies by Fc glycoengineering. The glycoantibodies of the invention may have improved therapeutic values compared to the corresponding monoclonal antibodies that have not been glycoengineered. | 2015-12-03 |
20150344560 | FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS - A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability. | 2015-12-03 |
20150344561 | FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS - A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability. | 2015-12-03 |
20150344562 | FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS - A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability. | 2015-12-03 |
20150344563 | FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS - A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability. | 2015-12-03 |
20150344564 | Viral Inactivation During Purification of Antibodies - Described herein are methods for isolating and purifying antibodies from a sample matrix. One aspect of the present disclosure is directed to viral reduction/inactivation of samples generated in the various steps of antibody purification. In a particular aspect, methods herein employ an acidification step followed by one or more chromatography steps. The chromatography steps can include one or more of the following chromatographic procedures: ion exchange chromatography, affinity chromatography, and hydrophobic interaction chromatography. | 2015-12-03 |
20150344565 | ANTIBODIES TO GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR - The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies. | 2015-12-03 |
20150344566 | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-13 AND/OR IL-17 - Engineered multivalent and multispecific binding proteins that bind IL-13 and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 2015-12-03 |
20150344567 | iPS/ES CELL-SPECIFIC ANTIBODY HAVING CYTOTOXICITY TO TARGET CELLS AND USE THEREOF - The present invention provides a monoclonal antibody that recognizes a lipid substance on an iPS cell surface and an ES cell surface as an epitope, and does not recognize EC cells, the antibody having a cytotoxic activity against a target cell, a method of producing a uniform differentiated cell population free of an undifferentiated cell, including contacting a cell population differentiated from an iPS or ES cell with the above antibody, and recovering viable cells, an agent for a cell transplantation therapy, containing a differentiated cell population obtained by the method, and the like. | 2015-12-03 |
20150344568 | TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS - This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay). Such predictive assays could for example be used to test whether a given ISV could have a tendency to give rise to such protein interference and/or such a signal; to select ISV's that are not or less prone to such protein interference or to giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an ISV will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and/or as an assay or test that can be used to guide modification or improvement of an ISV so as to reduce its tendency to give rise to such protein interference or signal; methods for modifying and/or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved ISV's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal. | 2015-12-03 |
20150344569 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AN INFLAMMATION - A method of treating a graft rejection disease in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of an isolated polypeptide comprising an antigen recognition domain capable of specifically binding a human scavenger receptor, wherein said antigen recognition domain comprises CDR amino acid sequences as set forth in SEQ ID NO: 11, 15, 19, 23, 27 and 31, thereby treating the graft rejection disease in the subject. | 2015-12-03 |
20150344570 | HETERODIMERIZED POLYPEPTIDE - The present inventors produced a heterodimerized polypeptide having an Fc region formed from two polypeptides with different amino acid sequences (a first polypeptide and a second polypeptide), and succeeded in producing a heterodimerized polypeptide containing an Fc region with improved function compared to that of a homodimer in which the Fc region is composed of only the first polypeptide or the second polypeptide by conventional technology. | 2015-12-03 |
20150344571 | ANTIBODY BINDING SPECIFICALLY TO HUMAN AND MOUSE L1CAM PROTEIN, AND USE THEREFOR - The present invention relates to a novel antibody specifically binding to human and mouse L1CAM, and more particularly, to an antibody binding to both human and mouse L1CAM with high affinity, which is prepared by modifying a sequence of an L1 cell adhesion molecule (L1CAM)-specific antibody comprising a heavy-chain variable region of SEQ ID NO. 1 and a light-chain variable region of SEQ ID NO. 5, a polynucleotide encoding the antibody, an expression vector comprising the polynucleotide, a transformant introduced with the vector, a pharmaceutical composition for preventing or treating cancer comprising the antibody, a method for treating cancer using the antibody, a composition for diagnosing cancer comprising the antibody, a kit for diagnosing cancer comprising the composition, a method for providing information for cancer diagnosis using the antibody, and an antibody-drug conjugate prepared by conjugating a drug to the antibody. | 2015-12-03 |
20150344572 | ANTI-CD160 SPECIFIC ANTIBODIES FOR THE TREATMENT OF EYE DISORDERS BASED ON NEOANGIOGENESIS - The present invention relates to the use of at least one anti-CD 160 antibody, preferably a compound selected from CL1-R2 monoclonal antibody (which may be obtained by the hybridoma CNCM 1-3204), its conservative fragments and its conservative derivatives, for preparing a drug designed to treat neovascular eye diseases. | 2015-12-03 |
20150344573 | HUMANIZED ANTI-CD22 ANTIBODY - Disclosed are humanized RFB4 antibodies or antigen-binding fragments thereof. therapy of B-cell associated diseases, such as B-cell malignancies, autoimmune disease and immune dysfunction disease. Preferably, hRFB4 comprises the light and heavy chain RFB4 CDR sequences with human antibody FR and constant region sequences, along with heavy chain framework region (FR) amino acid residues Q1, F27, V48, A49, F68, R98, T117 and light chain residues L4, S22, K39, G100, V104, and K107. More preferably, the heavy and light chain variable region sequences of hRFB4 comprise SEQ ID NO:7 and SEQ ID NO:8, respectively. In certain embodiments, trogocytosis (antigen shaving) induced by hRFB4 plays a significant role in determining antibody efficacy and disease responsiveness for treatment of B-cell diseases, such as hematopoietic cancers, immune system dysfunction and/or autoimmune disease. | 2015-12-03 |
20150344574 | FcGammaRIIB Specific Antibodies and Methods of Use Thereof - The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention. | 2015-12-03 |
20150344575 | FcGammaRIIB Specific Antibodies and Methods of Use Thereof - The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention. | 2015-12-03 |
20150344576 | HUMAN ANTI-KIR ANTIBODIES - Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects. | 2015-12-03 |
20150344577 | AGENTS FOR TREATING TUMORS, USE AND METHOD THEREOF - The present disclosure provides agents for treating and/or preventing resistance of tumor cells to radiation therapy (RT), the use and relevant method thereof. | 2015-12-03 |
20150344578 | ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15 - To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like. | 2015-12-03 |
20150344579 | PROCESS OF MODULATING MAN5 AND/OR AFUCOSYLATION CONTENT OF A GLYCOPROTEIN COMPOSITION - Provided is a method for producing glycoprotein composition with an increased percentage of Man5 and/or afucosylated glycans. Use of manganese for increasing the percentage of Man5 and afucosylated glycans in glycoprotein composition is further provided. | 2015-12-03 |
20150344580 | Human Monoclonal Antibodies Against Human Chemokine Receptor CCR7 - Aspects of this invention include fully human antibodies or fragments thereof that bind specifically to human CCR7 receptor. Such antibodies or fragments thereof can be used to treat disorders involving over function of the CCR7 receptor, including cancers. Other uses include detection of human CCR7 receptor in biological samples for diagnostic or evaluative purposes. Fully human antibodies against human CCR7 therefore can be used to diagnose disorders involving CCR7. Further, antibodies of this invention can be useful for treating disorders involving CCR7 by inhibiting binding of native chemokines to the CCR7, and thereby decrease effects of those chemokines. Anti-CCR7 antibodies of this invention can also be used as specific targeting agents to bring toxic agents to CCR7-expressing cells, to inhibit chemotaxis, and therefore can be effective therapeutic agents. | 2015-12-03 |
20150344581 | METHODS OF TREATING SKIN DISORDERS USING IL-31RA ANTAGONIST - The present invention relates to methods of treating patients suffering from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination by administering an IL-31RA antagonist. | 2015-12-03 |
20150344582 | HUMAN ANTI TSHR ANTIBODIES - According to one aspect there is provided An isolated human antibody molecule which binds to the TSHR and which reduces ligand-induced stimulation of the TSHR but has no effect on TSHR constitutive activity wherein the isolated human antibody molecule has the characteristic of patient serum TSHR autoantibodies of inhibiting TSH and M22 binding to the TSHR. | 2015-12-03 |
20150344583 | BCMA ANTIGEN BINDING PROTEINS - The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates and uses thereof. | 2015-12-03 |
20150344584 | Modified Antigen Binding Molecules With Altered Cell Signaling Activity - The present invention relates to modified antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies or fragments, including chimeric, primatized or humanized antibodies or fragments, having altered ability to mediate cell signaling activity by a target antigen, and/or altered ability to mediate cross-linking of one or more target antigens. In addition, the present invention relates to nucleic acid molecules encoding such modified ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the modified ABMs of the invention, and to methods of using these modified ABMs in treatment of disease. In addition, the present invention relates to modified ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function. | 2015-12-03 |
20150344585 | ANTI-CD20 GLYCOANTIBODIES AND USES THEREOF - The present disclosure relates to a novel class of anti-CD20 monoclonal antibodies comprising a homogeneous population of anti-CD20 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-CD20 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered. | 2015-12-03 |
20150344586 | Disulfide-Linked Multivalent MHC Class I Comprising Multi-function Proteins - Herein is reported a disulfide-linked multivalent multi-function protein, characterized in that it comprises two or more antigen presenting domains, exactly one antibody Fc-region, and at least one antigen binding site, wherein the antigen presenting domain comprises in N- to C-terminal direction either (i) a β2-microglobulin, and (ii) the extracellular domains α1, α2, and α3 of a class I MHC molecule with a relative frequency of less than 1%, or (i) a T-cell response eliciting peptide, (ii) a β2-microglobulin, and (iii) the extracellular domains α1, α2, and α3 of a class I MHC molecule with a relative frequency of 1% or more, wherein the antigen binding site binds to a cancer cell surface antigen or a virus-infected cell surface antigen and wherein the antigen presenting domain has at least two non-naturally occurring cysteine residues which form an intrachain/interdomain disulfide bond. | 2015-12-03 |
20150344587 | ANTI-HER2 GLYCOANTIBODIES AND USES THEREOF - The present disclosure relates to a novel class of anti-HER2 monoclonal antibodies comprising a homogeneous population of anti-HER2 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-HER2 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered. | 2015-12-03 |
20150344588 | MONOCLONAL ANTIBODIES AGAINST ACTIVATED PROTEIN C - The present invention provides monoclonal antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. Other antibodies inhibit both activated protein C and activation of unactivated protein C. Methods of treatment employing these antibodies are described herein as are methods of screening for and detecting these antibodies. | 2015-12-03 |
20150344589 | PHOSPHOHISTIDINE ANALOGS - The present invention relates to the phosphohistidine analogs of the present invention which of the formula | 2015-12-03 |
20150344590 | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1 and/or IL-17 - Engineered multivalent and multispecific binding proteins that bind IL-1β and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 2015-12-03 |
20150344591 | Sialic Acid Derivatives - An amine or hydrazide derivative of a sialic acid unit, e.g. in a polysaccharide, is reacted with a bifunctional reagent at least one of the functionalities of which is an ester of N-hydroxy succinimide, to form an amide or hydrazide product. The product has a useful functionality, which allows it to be conjugated, for instance to proteins, drugs, drug delivery systems or the like. The process is of particular utility for derivatising amine groups introduced in sialic acid terminal groups of polysialic acids. | 2015-12-03 |
20150344592 | FLUOROPOLYMER DISPERSION TREATMENT EMPLOYING OXIDIZING AGENT TO REDUCE FLUOROPOLYMER RESIN DISCOLORATION - A process for reducing thermally induced discoloration of fluoropolymer resin produced by polymerizing fluoromonomer in an aqueous dispersion medium to form aqueous fluoropolymer dispersion and isolating said fluoropolymer from the aqueous medium to obtain the fluoropolymer resin. The process comprises exposing the aqueous fluoropolymer dispersion to oxidizing agent. | 2015-12-03 |
20150344593 | Heterogeneous Ziegler-Natta Catalyst System And A Process For Olefin Polymerization Using The Same - The present disclosure provides a heterogeneous Ziegler-Natta catalyst system to be used in the preparation of ultra-high molecular weight polymers (UHMWP). The system includes at least one procatalyst, at least one co-catalyst, at least one hydrocarbon medium and at least one external donor, wherein the ratio of elemental magnesium to elemental titanium to halide, in the procatalyst, is 1:1.3:3.7; the ratio of elemental aluminum, present in the co-catalyst to elemental titanium, present in the procatalyst, ranges between 6:1 and 12:1; and the ratio of elemental silicon, present in the external donor to elemental titanium, present in the procatalyst, ranges between 1:10 and 10:1. The present disclosure also provides a process for preparation of UHMWPE using the heterogeneous Ziegler-Natta catalyst system of the present disclosure. | 2015-12-03 |
20150344594 | MAGNESIUM DICHLORIDE-ALCOHOL ADDUCTS AND CATALYST COMPONENTS OBTAINED THERE-FROM - Spherical adducts comprising a MgCl | 2015-12-03 |
20150344595 | CATALYST - A catalyst in solid particulate form free from an external carrier material comprising
| 2015-12-03 |
20150344596 | CATALYSTS - A catalyst comprising
| 2015-12-03 |
20150344597 | PRODUCTION OF SUBSTITUTED PHENYLENE DIBENZOATE INTERNAL ELECTRON DONOR AND PROCATALYST WITH SAME - The present disclosure is directed to the production of substituted phenylene aromatic diesters and 5-tert-butyl-3-methyl-1,2-phenylene dibenzoate (or “BMPD”) in particular. The processes disclosed herein produce a liquid BMPD product. The liquid BMPD product unexpectedly creates production efficiencies by reducing the number of production steps, reducing the amount and/or number of reagents required for BMPD production. The liquid BMPD product may also be utilized in procatalyst production yielding similar production efficiencies. The procatalyst composition is subsequently used for olefin polymerization. | 2015-12-03 |
20150344598 | USE OF A METALLOCENE CATALYST TO PRODUCE A POLYALPHA-OLEFIN - A process may include contacting an olefin monomer and a racemic bridged metallocene catalyst at a temperature of 80° C. to 150° C. in the presence of hydrogen. The racemic bridged metallocene catalyst may include a metallocene compound (A) and an activator component (B). The process may include recovering an effluent containing polyalpha-olefins (PAOs). The metallocene compound (A) may be represented by the formula R(Cp | 2015-12-03 |
20150344599 | ETHYLENE-BASED POLYMERS WITH IMPROVED MELT STRENGTH AND PROCESSES FOR THE SAME - The invention provides an ethylene-based polymer formed from at least the following: ethylene and a monomeric chain transfer agent (monomeric CTA) selected from Structure 1: wherein L is selected from a saturated hydrocarbon, a substituted saturated hydrocarbon, an unsaturated hydrocarbon, or a substituted unsaturated hydrocarbon; R1 is selected from hydrogen, a saturated hydrocarbon, a substituted saturated hydrocarbon, an unsaturated hydrocarbon, or a substituted unsaturated hydrocarbon; R2 is selected from hydrogen, a saturated hydrocarbon or a substituted saturated hydrocarbon; R3 is selected from hydrogen, a saturated hydrocarbon or a substituted saturated hydrocarbon; and R4 is selected from a saturated hydrocarbon, a substituted saturated hydrocarbon, an unsaturated hydrocarbon, or a substituted unsaturated hydrocarbon. | 2015-12-03 |
20150344600 | BIDIRECTIONAL SHAPE-MEMORY POLYMER, METHOD OF ITS PRODUCTION AND ITS USE - The present invention relates to an article consisting of or comprising a bidirectional shape-memory polymer (bSMP), the bSMP comprising: first phase-segregated domains (AD) having a first transition temperature (T | 2015-12-03 |
20150344601 | An Ethylene Based Polymer - The instant invention provides an ethylene based polymer. | 2015-12-03 |
20150344602 | A Polymerization Process for Producing Ethylene Based Polymers - The instant invention provides a polymerization process for producing ethylene based polymers. | 2015-12-03 |
20150344603 | ELASTIC TERPOLYMER AND PREPARATION METHOD THEREOF - The present invention relates to an elastic terpolymer that can acquire good mechanical properties and elasticity (flexibility) at the same time, and a preparation method thereof. The elastic terpolymer, which is a copolymer comprising 40 to 70 wt % of ethylene, 20 to 50 wt % of a C | 2015-12-03 |
20150344604 | Method of Preparing Fluoroelastomer Capable of Being Vulcanized by Using Peroxide - A method of preparing a fluoroelastomer capable of being vulcanized by using peroxide, the method comprising: in the presence of an initiator and a chain transfer agent, conducting emulsion polymerization reaction on comonomers to obtain a fluoroelastomer. The preparation method utilizes alkyl iodide RI | 2015-12-03 |
20150344605 | METHOD OF MAKING FLUOROPOLYMERS WITH A POLYIODIDE, COMPOSITIONS AND ARTICLES THEREOF - Described herein is a method of making a fluoropolymer and fluoropolymers thereof, wherein the method comprises: (a) providing an aqueous solution comprising a water soluble polyiodide salt of Formula (I): M | 2015-12-03 |
20150344606 | PROCESS TO PRODUCE POLYVINYL-ESTER COMPOSITIONS WITH LOW RESIDUAL MONOMER AND THE USE THEREOF - A process for reducing the amount of residual monomer in aqueous polymerization emulsion by using a sequential polymerization steps, The first step consists in adding an emulsion, of vinyl ester of alkyl of C1 to C18 carboxylic acids, to water containing a radical initiator, the second step consists in adding further an emulsion of alkyl acrylate and/or methacrylate, and the third step consists in c) adding to polymeric emulsion, resulting of the steps a) and b), pure liquid acrylate or methacrylate with alkyl chain of C | 2015-12-03 |
20150344607 | IMPRINTED POLYMER AND METHOD FOR PREPARING THE SAME - An imprinted polymer that is not electrically conductive is obtained by polymerization of at least one monomer with at least one crosslinking agent in the presence of a target. The polymer has in its structure at least one cavity having the shape of a target and at least one redox probe assuming either a polymerizable form or a non-polymerizable form. Methods are for preparing an imprinted polymer, for detecting a target implementing such a polymer. The polymer is used as a sensor, and more particularly an imprinted sensor, an active interface to manufacture electrochemical (bio)sensors, or to manufacture solid-phase extraction substrates. | 2015-12-03 |
20150344608 | COMPOSITION AND APPLICATIONS OF A MULTI-COMPONENT BENZO[1,2-B:4,5-B] DITHIOPHENE-DIFLUOROTHIENOTHIOPHENE RANDOMLY SUBSTITUTED POLYMERS FOR ORGANIC SOLAR CELLS - A polymer having two different sets of repeat units consisting essentially of: | 2015-12-03 |
20150344609 | SELF-ASSEMBLING POLYMERS - V - Disclosed are self-assembling diblock copolymers of the formula (I): | 2015-12-03 |
20150344610 | POLY(ETHER KETONE) POLYMERS COMPRISING CYCLOALIPHATIC UNITS - A poly(ether ketone) polymer comprising recurring units derived from the reaction of at least one aromatic dihalo compound comprising at least one —C(O)— group and at least one diol having a general formula HO-D | 2015-12-03 |
20150344611 | FOAM INSULATION UNIT - Insulating unit are disclosed which are prepared by a cavity-filling, fast-gelling rigid polyurethane foam based on a formulation comprising a polyol component which contains at least 5 weight percent of an amine-initiated polyols and 1.4 to 4 parts by weight of a catalyst package whereby the catalyst package contains at least one amine catalyst and the weight percent nitrogen present in the amine-initiated polyol to weight percent nitrogen present in the catalyst system is from 2 to 8. The formulation is injected into the cavity and the pressure in the cavity is subjected to reduced atmospheric pressure to achieve the rigid foam having a thermal conductivity of less than about 19 mW/mK at 10° C. average plate temperature. | 2015-12-03 |
20150344612 | NON-HOT-MELT 2,4-TDI-BASED POLYURETHANE COMPOSITION BEARING NCO END GROUPS AND HAVING A LOW CONTENT OF TDI MONOMER, COMPRISING AT LEAST ONE ISOCYANATE COMPOUND OF PARTICULAR MOLAR VOLUME - 1) Polyurethane composition comprising:
| 2015-12-03 |